Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strate... (Furthermore Bavarian Nordic has appointe...)

Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process

Date:4/2/2008

Furthermore, Bavarian Nordic has appointed a new CFO. Ole Larsen (42) will join the company as Executive Vice President Finance on 1 October 2008 at the latest. He currently holds the position as Finance Director and member of the management in Nordisk Film. Previously amongst others he worked as Finance Director at Berlingske Tidende.

Reiner Laus, MD., President & CEO of Bavarian Nordic's US subsidiary, BN ImmunoTherapeutics Inc., will also join the Executive Management. Reiner Laus was previously Vice President of Research and Development at Dendreon Corporation in Seattle, Washington where he was responsible for discovery, pre-clinical and development functions.
Executive Management hereafter consists of the following:

Anders Hedegaard, President & CEO

Nicolai Buhl Andersen, EVP Commercial Affairs

Paul Chaplin, EVP Research & Development

Reiner Laus, EVP, and CEO of BN ImmunoTherapeutics Inc.

Morten Max Rasmussen, EVP Transactions, Legal & IPR

Anders Gram, EVP Technical Operations

Ole Larsen, EVP Finance

Annual Report 2007 The full 2007 Annual Report was published on March 31, 2008 and is available for download on the company's website: http://www.bavarian-nordic.com

About Bavarian Nordic:

Bavarian Nordic, headquartered in Denmark, is a leading international biopharmaceutical company developing and producing innovative vaccines to prevent and treat infectious diseases and cancer.

In the U.S., Bavarian Nordic operates subsidiary companies, BN ImmunoTherapeutics, in Mountain View, California developing vaccines against cancers, and Bavarian Nordic Inc. in Washington, D.C. focused on business development, marketing, and government relations for the Bavarian Nordic Group.

For more information on Bavarian Nordic visit: http://www.bavarian-nordic.com

'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Vista Partners Updates Coverage; Maintains $3.20 Target Price
3. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
4. NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update
5. SGX Pharmaceuticals Provides Update on SGX523 Clinical Trials
6. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
7. ImaRx to Report Corporate Updates and 4Q07 Financial Results
8. LUMEDX Updates Real-Time Patient and Resource Scheduler for Healthcare Systems
9. InfuSystem Holdings Provides Business Update and Comments on Fourth Quarter 2007 Financial Results
10. Alexza to Announce 2007 Financial Results and Update Its Clinical Pipeline on Monday, March 17, 2008
11. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14

Post Your Comments:

Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strate...(Furthermore Bavarian Nordic has appointe...)